Explore more publications!

Nepal Healthcare Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Nepal Healthcare Times.

Press releases published on December 2, 2025

Clene to Provide CNM-Au8® ALS Program Update
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Conflicting Guidance and Rapid Innovation Leave Physicians Seeking Clarity in Relapsed/Refractory Multiple Myeloma
New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
Publication relating to transparency notifications
Publication relative à des notifications de transparence
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verano Awarded Conditional License to Commence Vertical Cannabis Operations in Texas
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
Zymeworks Announces Participation in Upcoming Conferences
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025
FISHER HOUSE FOUNDATION RECEIVES “FOUR STARS” FOR 22nd YEAR FROM CHARITY NAVIGATOR, A+ FROM CHARITY WATCH
Hawai’i Cancer Care and American Oncology Network Open New Kahului Clinic
Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight
AMPS Achieves HITRUST e1 Certification, Solidifying Commitment to Data Security in Healthcare
Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases
Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions